“…Zonulin, known as a regulator of epithelial and endothelial barrier functions, can reversibly increase intestinal permeability, activate the complement pathway (C3a and C5a) and promote the inflammatory response [ 35 , 36 ]. Recently, several studies have shown that serum zonulin levels were elevated in patients with gastrointestinal and non-gastrointestinal diseases, including type 1 diabetes mellitus, rheumatoid arthritis, non-coeliac gluten sensitivity, ulcerative colitis, Kawasaki disease, irritable bowel syndrome, acne rosacea and autism [ 14 , 17 , 20 , 21 , 28 , 30 , 37 ]. In this study, compared with healthy controls, elevated circulating zonulin levels were detected in both IgAV-N patients and IgAN patients, probably suggesting impaired intestinal permeability in IgAV-N and IgAN, which was also supportive of the previously proposed theory that intestinal mucosal immunity might play an important role in the pathogenesis of both IgAV-N and IgAN.…”